Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

Inclusion Criteria:

• Subjects with Ph+ (or BCR/ABL+) accelerated phase chronic myeloid leukemia whose disease has primary or acquired hematologic resistance to imatinib mesylate or who are intolerant of imatinib mesylate
• Men and women, 18 years of age or older
• Adequate hepatic function
• Adequate renal function
• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized
• ECOG performance status score 0 - 2

Exclusion Criteria:

• Women who are pregnant or breastfeeding
• A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
• Uncontrolled or significant cardiovascular disease
• Medications that increase bleeding risk
• Medications that change heart rhythms
• Dementia or altered mental status that would prohibit the understanding or rendering of informed consent
• History of significant bleeding disorder unrelated to CML
• Concurrent incurable malignancy other than CML
• Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy
• Prior therapy with BMS-35425
• Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study